DOCSLIB.ORG

Annual Report 2016 English

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2016 English ANNUAL REPORT 2016 CHECKLIST VISION Gerresheimer will become the leading global partner for enabling solutions that improve health and well-being. GOALS FOR 2016 GLOBAL MARKET LEADERSHIP IN PROFITABLE AND … … SUSTAINED GROWTH OUR MARKETS Clear focus on customers in the Adjusted EBITDA at constant exchange rates Revenue growth at constant exchange pharma, healthcare and cosmetics industry EUR 305m (+/- EUR 10m) rates EUR 1.4bn (+/- EUR 25m) Continuous improvement in quality – Average net working capital as % of revenues Secure future prospects with acquisitions focus on the patient (at constant exchange rates): 17% in 2016 and organic growth Innovation for new drugs and customer needs Cut net financial debt Capex about 8% of revenue at constant exchange rates Boost efficiency with state-of-the-art, globally Drive higher EPS standardized production technology Ensure verifiably sustainable operations Dividend of 20% to 30% of adjusted net Create capacity for future growth income after non-controlling interests Faster employee training and development 2016 RESULTS GLOBAL MARKET LEADERSHIP IN PROFITABLE AND … … SUSTAINED GROWTH OUR MARKETS Sale of Life Science Research Division Adjusted EBITDA at constant exchange Revenue at constant exchange rates for further focus on core business rates increased to EUR 311.3m increased to EUR 1,383.1m Scale up clean-room and Average net working capital at 15.8% of Growth notably from inhalers, plastic drug inspection technologies revenues – exceeding our expectations packaging, injection vials and cosmetic glass Launch new products for Net financial debt reduced by EUR 89.3m Capex program fully completed, volume ultrasensitive biotech drugs to EUR 788.2m; adjusted EBITDA leverage equivalent to 8.2% of revenue at constant improved from 2.9x to 2.6x exchange rates Pursuit of global machine strategy: standardization of tubular glass Adjusted earnings per share after non - Achieving our climate protection targets converting machines in Europe controlling interests increased significantly gets us top place in Carbon Disclosure Project by 23.8% to EUR 4.22 (2015: EUR 3.41) Modernization of cosmetic glass plant Above-average training rate in Germany; in Tettau (Germany) and expansion of Proposed dividend increase by successful German approach exported to Czech Republic and USA plant in Peachtree City (Georgia/USA) 23.5% to EUR 1.05 per share (approx. 25% payout ratio) for inhaler order OVERALL ASSESSMENT FOR 2016 1 OVERVIEW Gerresheimer is a leading global partner to the pharma and healthcare industry. With our specialty glass and plastic products, we contribute to health and well-being. We operate worldwide and, with some 10,000 employees, manufacture our products in local markets close to our customers. With our plants in Europe, North America, South America and Asia, we generate revenues of approximately EUR 1.4bn. Our comprehensive product portfolio includes pharmaceutical packaging and products for safe and simple drug delivery: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems, as well as packaging for the cosmetics industry. ON THE RIGHT TRACK Centor fully Global machinery strategy Dividend Co-op education programs exported integrated rolling in Europe increase to Horsovsky Tyn (Czech Republic) and Peachtree City, Georgia (USA) Expansion of inhaler plant in Peachtree City, Georgia (USA) Modernization of cosmetic glass plant in Tettau (Germany) Our innovative COP syringe presented at Pharma Days in Chicago Life Science Increased use of Research Division sold cleanroom technology in Butanta (Sao Paulo, Brazil), Boleslawiec (Poland) and Kundli (India) CONTENTS In Conversation with the Gerresheimer on the Independent Auditors‘ Financial Calendar/ Management Board Capital Markets Report Imprint On the Right Track Group Management Supervisory Board and Multi-Year Overview Report Management Board Report of the Divisions Supervisory Board Consolidated Financial Locations of Statements Gerresheimer AG Corporate Governance Responsibility Statement Report Product Overview Glossary 2 3 4 Uwe Röhrhoff Chief Executive Officer, responsible for Primary Packaging Glass Strategy & Planning Communication & Marketing Human Resources Legal & Compliance Business Excellence & Continuous Improvement The Annual Report carries the title our forecast. By contrast, our profit was at the upper “On the right track.” Is that how you end of our forecast. At constant exchange rates, would describe 2016? adjusted EBITDA increased to EUR 311.3m, pushing up Uwe Röhrhoff: our margin to over 22% for the first time, to 22.4%. Absolutely. It was a really eventful and successful Adjusted earnings after non-controlling interests per year for us. We had already made some key strategic share climbed to a record level of EUR 4.22. That is decisions in 2015 and, having continued to pursue this why we are proposing to increase the dividend by in 2016, can now focus even more on our core business 23.5% to EUR 1.05. and our customers. We have met our forecasts for all key performance indicators and have grown substan- The acquisition of Centor caused your debt level to tially. The Company is ready for the challenges ahead in rise in 2015. What does it look like now? the next few years. Rainer Beaujean: We believe that leverage measured in terms of net financial debt to adjusted EBITDA of 2.5x to be a “ The Company is ready for the prudent long-term course. The rating agencies give our Company an investment-grade rating, and that’s challenges ahead in the next how it should be. In order to bring leverage back few years.” down following the acquisition of Centor – which is our aim – we need a healthy cash flow. The operating Uwe Röhrhoff, Chief Executive Officer cash flow margin stood at 14.3% in 2016, that’s a good level. Average net working capital was at 15.8%, which is one percentage point better than we had Mr. Beaujean, we would be grateful for a anticipated at the start of the year. This, together with few details on the figures. the proceeds from the sale of the Life Science Research Rainer Beaujean: business, put us in a position to reduce debt more Certainly. As already mentioned, we reached all our quickly than many had expected. At the start of the targets. Our revenues are impressive. We grew by year, leverage was still at 2.9x. By the end of Novem- 7.2%. Revenues at constant exchange rates stood at ber, we had reduced it to 2.6x. EUR 1,383.1m, which is rather at the lower end of 5 You mentioned the sale of the Life Science Research business. Gerresheimer was in the laboratory glassware market for a long time. Why the sale now? Rainer Beaujean: For the last ten years, we had run our Life Science Research subsidiary as a joint venture with Chase Scientific. We have now sold it to the Duran Group. There was hardly any common ground or synergies with our core business. The markets, Rainer Beaujean customers and technologies were all different. For us, Chief Financial Officer, responsible for Life Science Research until the the sale was an important step toward focusing more sale as of October 31, 2016 on our core business: the manufacture and marketing of high-quality primary packaging for medicines and Finance Controlling cosmetics as well as drug delivery devices. Investor Relations Information Technology Internal Audit So is this the end of Gerresheimer’s big Mergers & Acquisitions buying and selling spree? Uwe Röhrhoff: We will continue to keep an eye out for companies that would be a good fit with us and would strengthen our technology portfolio, so as to expand the products and In addition to the strategic issues, was there services we offer our customers. Or companies that also a lot to do in operational terms? would allow us to broaden our regional presence. There Andreas Schütte: are no more sales in the pipeline. Definitely. The top priority for 2016 was to integrate Centor. Our new subsidiary is the market’s leading supplier of plastic containers for prescription medication “For us, the sale of the Life Science to US pharmacies. The business model works. Centor is thriving. The company has been integrated into the Research division was an important Gerresheimer environment with great success. Another step toward focusing more on our milestone was expanding the Peachtree City plant in the USA, where production has since started for a major core business.” order of inhalers for the USA. Rainer Beaujean, Chief Financial Officer Uwe Röhrhoff: In the Primary Packaging Glass Division, the no. 1 So manufacturing cosmetics packaging is part of priority was the ongoing standardization and modern- your core business, and that’s not up for sale? ization of production machinery. On top of this, Uwe Röhrhoff: important investments were made in the quality of our That’s right. products and services. And not to leave out cosmetics: Our staff at the cosmetic glass plant in Tettau, Germany, carried out a major furnace overhaul in record time. Our cosmetic glass plants, which are highly innovative, bring some 100 new products to market every year. 6 We have further expanded the decorating capacities unique offering. Implementing this plan is very high needed for this. All these operational initiatives on our list of priorities. From pharmaceutical vials and serve to boost our efficiency, enhance our quality prefillable syringes all the way to autoinjectors, we and cut our costs. can deliver all-in solutions for any drug and thus set ourselves well apart from the competition. And we can How are customer requirements changing and offer them in glass, plastic and all kinds of customized how are you responding? variations. Uwe Röhrhoff: The customer and the patient are at the center of Here are two examples for the good old material of everything we do. Our priorities are offering top quality, glass.
Load more

Recommended publications
  • Equity Valuation of Gerresheimer AG
    Equity Valuation of Gerresheimer AG Martin Kreuzer Dissertation written under the supervision of José Carlos Tudela Martins Dissertation submitted in partial fulfilment of requirements for the MSc in International Management, at the Universidade Católica Portuguesa, June 4th, 2019. Recommendation: Buy Gerresheimer AG Current price as of May 8th, 2019: 69€ Healthcare / Pharma Price Target: 78€ Reuters: GXIG.DE Investment Summary Growing…. slowly, but surely Profile After rough years, the new CEO puts Gerresheimer back on closing price 69 € “growth-path” and presents a promising mid-term outlook. I Market Cap (€m) 2.434 EV (€m) 3.617 therefore issue a buy recommendation targeting a price of 78€, Shares outstanding (m) 31,4 which represents an upside potential of 15% compared to a Free float 100% th P/E 28x current share price of 69€ as of May 8 , 2019. When comparing EV/EBITDA 13x it to the price as of valuation date (63€) the upside potential Net Debt/EBITDA 47% Dividend Yield (2019) 1,4% amounts to 24%. Gerresheimer gets tailwind from stable Beta 1,1 industry and macroeconomic outlooks and will particularly profit from arising megatrends. Fianancials: PPG & P&D €m 2018 2019 2020 Strong year 2018 and even stronger mid-term guidance Revenue 1.355 1.397 1.435 EBITDA 274 269 279 2018 was strong with an adjusted EBITDA of 294 EURm and Net Income 139 81 83 sales of 1.433 EURm on a group basis. The valuation based on ROIC 10,5% 5,9% 5,9% FCF 126 63 68 its individual parts, PPG and P&G, and its newly acquired Advanced Technologies division, result in an EV of 3.617 Sum of the parts Valuation EURm.
    [Show full text]
  • Euro Stoxx® Multi Premia Index
    EURO STOXX® MULTI PREMIA INDEX Components1 Company Supersector Country Weight (%) SARTORIUS STEDIM BIOTECH Health Care France 1.59 IMCD Chemicals Netherlands 1.25 VOPAK Industrial Goods & Services Netherlands 1.15 BIOMERIEUX Health Care France 1.04 REMY COINTREAU Food, Beverage & Tobacco France 1.03 EURONEXT Financial Services France 1.00 HERMES INTERNATIONAL Consumer Products & Services France 0.94 SUEZ ENVIRONNEMENT Utilities France 0.94 BRENNTAG Chemicals Germany 0.93 ENAGAS Energy Spain 0.90 ILIAD Telecommunications France 0.89 DEUTSCHE POST Industrial Goods & Services Germany 0.88 FUCHS PETROLUB PREF Chemicals Germany 0.88 SEB Consumer Products & Services France 0.87 SIGNIFY Construction & Materials Netherlands 0.86 CARL ZEISS MEDITEC Health Care Germany 0.80 SOFINA Financial Services Belgium 0.80 EUROFINS SCIENTIFIC Health Care France 0.80 RATIONAL Industrial Goods & Services Germany 0.80 AALBERTS Industrial Goods & Services Netherlands 0.74 KINGSPAN GRP Construction & Materials Ireland 0.73 GERRESHEIMER Health Care Germany 0.72 GLANBIA Food, Beverage & Tobacco Ireland 0.71 PUBLICIS GRP Media France 0.70 UNITED INTERNET Technology Germany 0.70 L'OREAL Consumer Products & Services France 0.70 KPN Telecommunications Netherlands 0.68 SARTORIUS PREF. Health Care Germany 0.68 BMW Automobiles & Parts Germany 0.68 VISCOFAN Food, Beverage & Tobacco Spain 0.67 SAINT GOBAIN Construction & Materials France 0.67 CORBION Food, Beverage & Tobacco Netherlands 0.66 DAIMLER Automobiles & Parts Germany 0.66 PROSIEBENSAT.1 MEDIA Media Germany 0.65
    [Show full text]
  • Annual Report 2010
    Overview Annual Report 2010 Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our wide product spectrum ranges from pharmaceutical vials to complex drug delivery systems, such as syringe systems, insulin pens and inhalers, for safe dosage and application. Together with our partners we develop solutions which set standards and have role-model status throughout their respective business sectors. Smaller shares of the business are attributable to products for the cosmetics industry and niche segments of the food and beverage Gerresheimer AG industry. Benrather Strasse 18-20 In our 44 locations in Europe, North and South America and 40213 Duesseldorf ANNUAL REPORT 2010 Germany Asia we employ around 9,500 people. Through top-class Phone +49 211 6181-00 Fax +49 211 6181-295 technologies, convincing innovations and targeted investments we E-mail [email protected] are systematically expanding our strong market position. www.gerresheimer.com REVENUES BY MARKET SEGMENT REVENUES BY REGION Consolidated revenues: EUR 1,025m Consolidated revenues: EUR 1,025m Europe 63 % Pharma and Healthcare 82 % Americas 30 % 2010 2010 Cosmetics 12 % Other 6 % Other 7 % PREFACE SUCCESS FACTORS MANAGEMENT SHARES COMBINED MANAGEMENT REPORT CONSOLIDATED FINANCIAL STATEMENTS FURTHER INFORMATION Group Key Figures Segment Key Figures Financial Calendar Group Key Figures (IFRS) Segment Key Figures Change February 10, 2011 Annual Report 2010 Financial Year
    [Show full text]
  • Vanguard Total World Stock Index Fund Annual Report October 31, 2020
    Annual Report | October 31, 2020 Vanguard Total World Stock Index Fund See the inside front cover for important information about access to your fund’s annual and semiannual shareholder reports. Important information about access to shareholder reports Beginning on January 1, 2021, as permitted by regulations adopted by the Securities and Exchange Commission, paper copies of your fund’s annual and semiannual shareholder reports will no longer be sent to you by mail, unless you specifically request them. Instead, you will be notified by mail each time a report is posted on the website and will be provided with a link to access the report. If you have already elected to receive shareholder reports electronically, you will not be affected by this change and do not need to take any action. You may elect to receive shareholder reports and other communications from the fund electronically by contacting your financial intermediary (such as a broker-dealer or bank) or, if you invest directly with the fund, by calling Vanguard at one of the phone numbers on the back cover of this report or by logging on to vanguard.com. You may elect to receive paper copies of all future shareholder reports free of charge. If you invest through a financial intermediary, you can contact the intermediary to request that you continue to receive paper copies. If you invest directly with the fund, you can call Vanguard at one of the phone numbers on the back cover of this report or log on to vanguard.com. Your election to receive paper copies will apply to all the funds you hold through an intermediary or directly with Vanguard.
    [Show full text]
  • FACTSHEET - AS of 27-Sep-2021 Deutschland Ethik 30 Aktienindex
    FACTSHEET - AS OF 27-Sep-2021 Deutschland Ethik 30 Aktienindex HISTORICAL PERFORMANCE 300 250 200 150 100 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Deutschland Ethik 30 Aktienindex CHARACTERISTICS ISIN / WKN DE000SLA8ET8 / SLA8ET Base Value / Base Date 100 Points / 31.12.2013 Bloomberg / Reuters DETHIP30 Index / .DETHIP30 Last Price 290.19 Index Calculator Solactive AG Dividends Not included (Price index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 31.12.2013 Index Members 30 FACTSHEET - AS OF 27-Sep-2021 Deutschland Ethik 30 Aktienindex STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -2.05% -0.50% 4.31% 18.22% 8.80% 54.20% Performance (p.a.) - - - - - 5.75% Volatility (p.a.) 12.00% 11.76% 11.67% 14.61% 12.36% 18.47% High 296.27 298.82 298.82 298.82 298.82 298.82 Low 282.92 282.92 278.19 225.13 261.73 158.75 Sharpe Ratio -1.81 -0.12 0.81 1.30 1.02 0.34 Max. Drawdown -4.51% -5.32% -5.32% -11.56% -5.32% -41.72% VaR 95 \ 99 -23.1% \ -40.4% -28.6% \ -53.0% CVaR 95 \ 99 -36.1% \ -61.6% -45.3% \ -74.2% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE 100.0% TOP COMPONENTS AS OF 27-Sep-2021 Company Ticker Country Currency Index Weight (%) SAP SE SAP GY Equity DE EUR 9.88% SIEMENS AG SIE GY Equity DE EUR 9.79% ALLIANZ SE ALV GY Equity DE EUR 8.98% DEUTSCHE POST AG DPW GY Equity DE EUR 7.74% ADIDAS AG ADS GY Equity DE EUR 6.21% LEG IMMOBILIEN SE LEG GY Equity DE EUR 6.03% TELEFONICA DEUTSCHLAND HOLDING AG O2D GY Equity DE EUR
    [Show full text]
  • Fact Sheet As of 06/30/2021
    iShares MSCI Germany Small-Cap ETF EWGS Fact Sheet as of 06/30/2021 The iShares MSCI Germany Small-Cap ETF seeks to track the investment results of an index composed of small-capitalization German equities. KEY FACTS Fund Launch Date 01/25/2012 Expense Ratio 0.59% WHY EWGS? Benchmark MSCI Germany Small Cap 1 Exposure to small public companies in Germany Index 2 Targeted access to small-cap German stocks 30 Day SEC Yield 1.15% Number of Holdings 114 3 Use to express a view on a single country market segment; pair with EWG for Net Assets $44,662,441 comprehensive Germany coverage Ticker EWGS CUSIP 46429B465 GROWTH OF 10,000 USD SINCE INCEPTION Exchange Cboe BZX formerly known as BATS TOP HOLDINGS (%) EVOTEC 3.59 DIALOG SEMICON PLC 3.41 TAG IMMOBILIEN AG 2.80 RHEINMETALL AG 2.59 THYSSENKRUPP AG 2.54 CTS EVENTIM AG 2.17 GERRESHEIMER AG 2.09 HUGO BOSS N AG 1.96 Fund Benchmark PROSIEBEN SAT.1 MEDIA N 1.95 The Growth of $10,000 chart reflects a hypothetical $10,000 investment and assumes BEFESA SA 1.85 reinvestment of dividends and capital gains. Fund expenses, including management fees and 24.95 other expenses were deducted. Holdings are subject to change. PERFORMANCE 1 Year 3 Year 5 Year 10 Year Since Inception NAV 45.05% 12.17% 17.13% N/A 14.97% Market Price 44.80% 12.38% 17.06% N/A 14.98% Benchmark 44.96% 12.07% 16.96% 10.56% 14.82% The performance quoted represents past performance and does not guarantee future results.
    [Show full text]
  • ESG Monitor 2020 Das Ranking
    ESG Monitor 2020 Das Ranking Ein Gemeinschaftsprojekt von: & ESG - MONITOR 2020 © cometis AG und KOHORTEN 1 Sozial & Wirtschaftsforschung GmbH & C.KG Die besten ESG-Berichte der DAX und MDAX-Unternehmen 2018 »Es mögen Fische sterben oder Menschen, das Baden in Seen und Flüssen mag Krankheiten erzeugen, es mag kein Öl mehr aus den Pumpen kommen und die Durchschnittstemperaturen mögen sinken oder steigen, solange darüber nicht kommuniziert wird, hat dies keine gesellschaftlichen Auswirkungen.« Niklas Luhmann, 1986 Kommunikation als gesellschaftliche Operation in: Ökologische Kommunikation: Kann die Gesellschaft sich auf ökologische Gefährdungen einstellen?, hrsg. v. Niklas Luhmann, Opladen ESG - MONITOR 2020 Disclaimer Diese Untersuchung gibt die Meinung der Autoren der cometis AG und der KOHORTEN Sozial- & Wirtschaftsforschung GmbH & Co.KG wieder und erhebt bei aller von uns angewandten Sorgfalt keinen Anspruch auf Richtigkeit und Vollständigkeit der dargestellten Informationen. Die Untersuchung stellt weder ein Angebot, noch eine Empfehlung oder eine Beratung dar. Das von uns dargestellte "Ranking" beinhaltet auch keine Bewertung der dargestellten Unternehmen im Ganzen. © cometis AG und KOHORTEN 2 Sozial & Wirtschaftsforschung GmbH & C.KG Grundlagen für das Ranking Grundlage für das Ranking ist das Datenerfassungstool des ESG-Monitors 2019. Die Auswertung erfolgte durch das finanzmarkterfahrene Team der cometis AG. Bewertet wurde die ESG-Berichterstattung (NFE, NFB) des Berichtsjahres 2018. Untersucht wurden Messbarkeit, Transparenz, Vergleichbarkeit
    [Show full text]
  • Gerresheimer AG ANNUAL REPORT 2019
    OUR FOUNDATION FOR GROWTH Change Financial Year-end November 30 2019 2018 in %7) 2017 2016 2015 2014 Results of Operations during Reporting Period in EUR m Revenues 1,392.3 1,367.7 1.8 1,348.3 1,375.5 1,282.911) 1,207.911) Adjusted EBITDA1) 400.0 298.6 34.0 310.8 307.8 262.611) 241.011) in % of revenues 28.7 21.8 – 23.1 22.4 20.511) 20.011) Adjusted EBITA2) 294.6 202.1 45.8 219.5 220.9 178.111) 155.111) in % of revenues 21.2 14.8 – 16.3 16.1 13.911) 12.811) Results of operations 123.8 139.5 -11.3 180.8 180.5 182.011) 120.711) Adjusted net income3) 227.7 180.3 26.3 130.0 130.49) 117.712) 97.912) Net Assets as of Reporting Date in EUR m Total assets 2,641.2 2,730.9 -3.3 2,444.1 2,374.3 2,419.4 1,655.9 Equity 941.6 890.1 5.8 789.5 763.3 698.1 604.4 Equity ratio in % 35.6 32.6 – 32.3 32.1 28.9 36.5 Net working capital 183.0 202.7 -9.7 185.7 200.3 213.7 233.1 in % of revenues of the preceding twelve months 13.1 14.8 – 13.8 14.6 16.711) 19.411) Capital expenditure 185.4 114.7 61.6 118.6 113.2 125.8 126.6 Net financial debt 942.7 886.4 6.4 712.7 788.2 877.5 423.8 Adjusted EBITDA leverage4) 2.4 3.1 – 2.3 2.6 2.9 1.7 Financial and Liquidity Position during Reporting Period in EUR m Cash flow from operating activities 192.9 173.4 11.2 219.2 173.5 203.8 158.3 Cash flow from investing activities -203.2 -286.9 -29.2 -112.1 7.9 -600.1 -125.0 thereof cash paid for capital expenditure -163.9 -114.6 43.1 -116.5 -110.7 -125.8 -125.6 Free cash flow before financing activities -10.3 -113.5 -90.9 107.1 181.3 -396.3 33.3 Employees Employees as of the reporting
    [Show full text]
  • Authorizations for Capital Raisings and Convertible Bond Issues 2015
    Authorizations for Capital Raisings and Convertible Bond Issues DAX® and German MDAX® Companies (Based on 2015 Annual Meetings) © 2016 Cleary Gottlieb Steen & Hamilton LLP. All rights reserved. Preface This booklet presents a summary overview of authorizations for capital raisings and convertible bond issuances of all DAX® and German MDAX® companies based on their 2015 annual general meetings. The amount of any authorized capital reflected in this booklet takes into account any issuance of shares out of authorized capital entered into the commercial register prior to December 2015. The amount of any convertible bond authorization and underlying conditional capital reflected in this booklet takes into account the issuance of any convertible bonds based on such authorization prior to December 2015 and the amount of conditional capital underlying such convertible bonds as more fully described in this booklet. All information regarding the free float of the selected companies as of the last index rebalancing date in December 2015 was taken from a website of Deutsche Börse AG (www.dax-indices.com) where such information can be found under “Downloads” → “Composition & Indicators” → “Composition DAX” and “Composition MDAX”. Deutsche Börse AG regularly calculates the free float for index weighting purposes according to the definition set out in Section 2.3 of the “Guide to the Equity Indices of Deutsche Börse” which is also available under www.dax-indices.com (“Downloads” → “Guides & Factsheets”). Inclusion in the DAX® and MDAX® requires, among other things, a minimum free float of 10%. We hope you will find this booklet useful. We will be pleased to answer any queries you may have in connection with the information presented in this booklet.
    [Show full text]
  • Dienstwagen Börsennotierter Und Mittelständischer Unternehmen 2015 10-12 Punkte 4-9 Punkte 0-3 Punkte Bewertungskriterien Zur Punktevergabe Siehe Seite 6
    – 1/6 – Grüne Karte: Gelbe Karte: Rote Karte: Dienstwagen börsennotierter und mittelständischer Unternehmen 2015 10-12 Punkte 4-9 Punkte 0-3 Punkte Bewertungskriterien zur Punktevergabe siehe Seite 6 Unternehmen Name Fahrzeug Ø CO2-Ausstoß Ø CO2-Ausstoß Ø CO2-Ausstoß Punkte Gesamt- Bewer- Vorsitzender Vorstand / Vorsitzender Vorstand / Fahrzeug Vorstands- Unternehmens- Mobilitäts- punkt- tung Vorsitzender flotte flotte strategie Geschäftsführung Geschäftsführung zahl [g/km] [g/km] [g/km] Tengelmann Warenhandels- Karl-Erivan W. Haub Tesla Model S Performance (Elektro) 1031) 99 124 4 12 gesellschaft KG Audi A6 Avant 3.0 TDI clean diesel quattro Allianz Deutschland AG Dr. Manfred Knof 138 112 117 4 11 (Diesel) Coca-Cola Deutschland GmbH Bianca Bourbon Mercedes Benz E300 BlueTEC Hybrid (Diesel) 119 124 120 3 11 FRoSTA AG Felix Ahlers VW up! 1.0 BMT (Benzin) 98 135 124 4 11 IKEA Deutschland GmbH & Co. KG Peter Betzel VW Passat 2,0 TDI BlueMotion (Diesel) 119 119 113 3 11 Tchibo GmbH Dr. Markus Conrad BMW i3 Range Extender (Benzin/Elektro) 902) 146 118 4 11 Deutsche Telekom AG Timotheus Höttges Mercedes Benz S350 BlueTEC 4MATIC (Diesel) 156 140 117 4 10 Drägerwerk AG & Co. KGaA Stefan Dräger Tesla Model S Performance (Elektro) 1031) 79 115 2 10 DuPont de Nemours (Deutschland) Christian Beers Mercedes Benz E300 BlueTEC Hybrid (Diesel) 116 123 127 2 10 GmbH Kaiser’s Tengelmann GmbH Raimund Luig Audi A6 Avant 3.0 TDI (Diesel) 156 148 118 4 10 Mercedes Benz E300 BlueTEC Hybrid Kombi Pfeiffer Vacuum GmbH Manfred Bender 116 133 119 3 10 (Diesel) Mercedes Benz CLS Shooting Brake 350 CDI SMA Solar Technology AG Pierre-Pascal Urbon 159 117 128 4 10 (Diesel) 1) 2) CO2-Ausstoß des Tesla Model S: Stromverbrauch von 18,1 kWh/100km (103g CO2/km) unter Berücksichtigung der spezifischen CO2-Emissionen des deutschen Strommix 2014 von 569 g/kWh (Quelle: Umweltbundesamt).
    [Show full text]
  • WOMEN-ON-BOARD-INDEX III Aufsichtsräte (Stand 14.06.2012) Powered by Fidar
    WOMEN-ON-BOARD-INDEX III Aufsichtsräte (Stand 14.06.2012) powered by FidAR Zahl Anteil WoB-Index Posit Zahl AR- Unternehmen Notierung Frauen Frauen nur ion Mitgl. AR AR Aufsichtsräte 1 Douglas Holding AG MDAX 16 8 50% 50,00% 1 TAG Immobilien AG SDAX 6 3 50% 50,00% 3 Kabel Deutschland Holding AG MDAX 12 5 42% 41,67% 4 Deutsche Bank AG DAX 20 8 40% 40,00% 5 Amadeus Fire AG SDAX 12 4 33% 33,33% 5 Bechtle AG TecDAX 12 4 33% 33,33% 5 Beiersdorf AG DAX 12 4 33% 33,33% 5 Bertrandt AG SDAX 6 2 33% 33,33% 5 Biotest AG SDAX 6 2 33% 33,33% 5 centrotherm photovoltaics AG TecDAX 3 1 33% 33,33% 5 CeWe Color Holding AG SDAX 6 2 33% 33,33% 5 HAMBORNER REIT SDAX 9 3 33% 33,33% 13 Henkel AG & Co. KGaA DAX 19 6 32% 31,58% 14 Deutsche Post AG DAX 20 6 30% 30,00% 14 GfK SE SDAX 10 3 30% 30,00% 16 Sky Deutschland AG MDAX 7 2 29% 28,57% 17 Allianz SE DAX 12 3 25% 25,00% 17 Commerzbank AG DAX 20 5 25% 25,00% 17 Deutsche Telekom AG DAX 20 5 25% 25,00% 17 Fielmann AG MDAX 16 4 25% 25,00% 17 Fraport AG MDAX 20 5 25% 25,00% 17 freenet AG TecDAX 12 3 25% 25,00% 17 Gerresheimer AG MDAX 12 3 25% 25,00% 17 Merck KGaA DAX 16 4 25% 25,00% 17 SAP AG DAX 16 4 25% 25,00% 17 Software AG TecDAX 12 3 25% 25,00% 17 Symrise AG MDAX 12 3 25% 25,00% 17 TUI AG MDAX 16 4 25% 25,00% 29 Axel Springer AG MDAX 9 2 22% 22,22% 29 Deutsche Börse AG DAX 18 4 22% 22,22% 29 Hannover Rückversicherung AG MDAX 9 2 22% 22,22% 29 STADA Arzneimittel AG MDAX 9 2 22% 22,22% 33 comdirect bank AG SDAX 5 1 20% 20,00% 33 GSW Immobilien AG MDAX 5 1 20% 20,00% 33 Hawesko Holding AG SDAX 5 1 20% 20,00% 33
    [Show full text]
  • Management Report and Financial Statements of Gerresheimer AG
    Management Report and Notes to the Financial Statements of Gerresheimer AG 2009 INNOVATIVE. GLOBAL. CONTENT 1 Management Report 15 Financial Statements 1 Functions and Structure 15 Income Statement of Gerresheimer AG 16 Balance Sheet 1 Portfolio Changes 18 Statement of Changes in Fixed Assets 1 Development of Gerresheimer AG's 20 Notes to the Financial Statements Results of Operations 45 Responsibility Statement 2 Development of the Net Assets and Financial Situation of Gerresheimer AG 46 Audit Opinion 3 Assessment of Business Development 47 List of Shareholdings 3 Employees 50 Supervisory Board and 3 Research & Development Management Board 4 Disclosures Pursuant to sec. 289 (4) HGB [”Handelsgesetzbuch“: German Commercial Code] and Explanatory Report 7 Remuneration of the Management Board 8 Risk Report 11 Events After the Balance Sheet Date 12 Outlook MANAGEMENT REPORT FINANCIAL STATEMENTS FURTHER INFORMATION MANAGEMENT REPORT OF GERRESHEIMER AG FOR THE FINANCIAL YEAR FROM DECEMBER 1, 2008 TO NOVEMBER 30, 2009 FUNCTIONS AND STRUCTURE of GErrESHEIMER AG Gerresheimer AG is the parent company of the Gerresheimer Group and as a holding company manages its direct and indirect subsidiaries. At the end of the financial year 2009, the Group had 40 sites in Europe, the Americas and China, and 9,343 employees worldwide. The Gerresheimer Group is an internationally leading supplier of high-quality glass and plastic packaging and system solutions. Its most important sales market is the global pharma & life science industry. Based on own developments and state-of-the-art production technologies, Gerresheimer offers primary pharmaceu- tical packaging and drug delivery systems as well as diagnostic systems and the full range of glass products for the life science industry.
    [Show full text]